SBRX9

SBRX9 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and memory impairment. The drug is part of Stramsen's pipeline of natural pharmaceutical alternatives, which are derived from a proprietary database of thousands of medicinal plants. SBRX9 is designed to improve attention and memory, aiming to provide a safer therapeutic profile with fewer side effects compared to traditional synthetic stimulants or cognitive enhancers. As a biopharmaceutical candidate, it represents the company's approach to leveraging natural compounds for complex neurological and behavioral conditions.